Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer

Tumor Biology

Volumn 36, Issue 9, 2015, Pages 6751-6758

  Peng, Wei ^a   Wu, Guoqiu ^b   Fan, Hong ^c   Wu, Jianzhong ^a   Feng, Jifeng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^c First People's Hospital of Yunnan Province   (China)

Author keywords

Biomarker; Gastric cancer; Prognosis; SPRY4 IT1; Tumorigenesis

Indexed keywords

CYCLINE; LONG NONCODING RNA SPRY4 INTRONIC TRANSCRIPT 1; LONG UNTRANSLATED RNA; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG; TUMOR MARKER;

AGS CELL LINE; ARTICLE; BGC 823 CELL LINE; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL PROLIFERATION; CLINICAL FEATURE; COLONY FORMATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GASTRIC CANCER CELL LINE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENETIC ASSOCIATION; HGC 27 CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MGC80 3 CELL LINE; MKN 45 CELL LINE; OVERALL SURVIVAL; PRIORITY JOURNAL; SGC 7901 CELL LINE; STOMACH CANCER; TUMOR INVASION; TUMOR VOLUME; ADULT; AGED; CELL MOTION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TUMOR CELL LINE;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RNA, LONG NONCODING; STOMACH NEOPLASMS;

EID: 84947129291     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3376-4     Document Type: Article

References (23)

1. Hartgrink HH, Jansen EPM, van Grieken NCT, van de Velde CJH. Gastric cancer. Lancet. 2009;374(9688):477–90. doi:10.1016/s0140–6736(09)60617–6.
2. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer a meta-analysis. Jama–J Am Med Assoc. 2010;303(17):1729–37. doi:10.1001/jama.2010.534.
3. Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci. 2010;14(4):302–8.
4. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41. doi:10.1016/j.cell.2009.02.006.
5. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23(13):1494–504. doi:10.1101/gad.1800909.
6. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21(6):354–61. doi:10.1016/j.tcb.2011.04.001.
7. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, et al. Long noncoding RNA HOTAIR regulates polycomb–dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011;71(20):6320–6. doi:10.1158/0008-5472.can-11-1021.
8. Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180–9. doi:10.1158/0008-5472.can-12-2850.
9. Panzitt K, Tschernatsch MMO, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007;132(1):330–42. doi:10.1053/j.gastro.2006.08.026.
10. Peng W, Gao W, Feng J. Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol. 2014;31(12):1–7.
11. Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, et al. The melanoma–upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res. 2011;71(11):3852–62. doi:10.1158/0008-5472.can-10-4460.
12. Xie HW, Wu QQ, Zhu B, Chen FJ, Ji L, Li SQ, et al. Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumor Biol. 2014;35(8):7743–54. doi:10.1007/s13277-014-2013-y.
13. Sun M, Liu XH, Lu KH, Nie FQ, Xia R, Kong R, et al. EZH2–mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial–mesenchymal transition. Cell Death Dis. 2014;5:e1298. doi:10.1038/cddis.2014.256.
14. Zou YF, Jiang ZY, Yu X, Sun M, Zhang YY, Zuo Q, et al. Upregulation of long noncoding RNA SPRY4-IT1 modulates proliferation, migration, apoptosis, and network formation in trophoblast cells HTR–8SV/neo. PLos One. 2013;8(11):e79598. doi:10.1371/journal.pone.0079598.
15. Wang X, Yu HG, Lu XY, Zhang P, Wang ML, Hu YK. miR–22 suppresses the proliferation and invasion of gastric cancer cells by inhibiting CD151. Biochem Biophys Res Commun. 2014;445(1):175–9. doi:10.1016/j.bbrc.2014.01.160.
16. Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362(9380):305–15. doi:10.1016/s0140-6736(03)13975-x.
17. Tsai MC, Spitale RC, Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res. 2011;71(1):3–7. doi:10.1158/0008-5472.can-10-2483.
18. Maruyama R, Suzuki H. Long noncoding RNA involvement in cancer. BMB Rep. 2012;45(11):604–11. doi:10.5483/BMBRep.2012.45.11.227.
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
20. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther. 2002;1(3):226–31.
21. Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol. 2003;15(2):158–63. doi:10.1016/s0955–0674(03)00008–5.
22. Overall CM, Lopez–Otin C. Strategies for MMP inhibition in cancer: innovations for the post–trial era. Nat Rev Cancer. 2002;2(9):657–72. doi:10.1038/nrc884.
23. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont E. The possible role of matrix metalloproteinase (MMP)–2 and MMP–9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol. 2004;50(2):87–100. doi:10.1016/j.critevonc.2003.09.001.